SSI Diagnostica Group will as of 2nd of January 2025 welcome Lars Henrik Vejrup Hansen as new Group CFO. Lars comes from prior senior financial leadership positions in organizations like Ernst & Young and A. P. Møller Maersk – and most recently from a position as Group CFO at Toms Gruppen A/S.

“I am very pleased to welcome Lars to our organization! Lars has extensive experience in similar financial roles and strong leadership skills – and he will be an excellent fit with our organization, and with the strategy we recently embarked on”, says CEO Christina Lindved.

In 2023, SSI Diagnostica Group introduced a new five-year strategy, focusing on the core business and integration of recent acquisitions. In 2024, this focus on core business growth, combined with increasing realizations of synergies from the acquisitions, has established a solid foundation for SSI Diagnostica Group to accelerate growth in the coming years.

Chairman of the Board, Homi Shamir adds:

“Lars is a valuable addition to the management team as we work towards expanding SSI Diagnostica Group’s global presence and advancing diagnostic solutions to improve treatment outcomes for patients”.

SSI Diagnostica Group is a partner, developer, and manufacturer to the diagnostic industry – experts in clinical diagnostics within infectious diseases. The Group is owned by Adelis Equity Partners.